Document is current

Article History

Received: 1 July 2024

Accepted: 7 July 2025

First Online: 11 August 2025

Declarations

:

: The Swedish Medical Product Agency, local ethics and radiation safety protection committees approved this study. The conduct of the study followed the ethical principles of the current Declaration of Helsinki, International Conference on Harmonisation for Good Clinical Practice, and applicable regulatory requirements.

: All participants provided written informed consent after the nature and possible consequences of the study procedures were explained, and prior to enrollment in the study.

: The participant’s written informed consent covered consent to publish anonymized individual data.

: The content of this publication is solely the responsibility of the authors and does not necessarily represent the official views of Bristol-Myers Squibb or ConSynance. Shuang Liu is the founder and an employee of ConSynance Therapeutics, Inc., and owns stocks. Rob Risinger, Harald Murck, and Roger Lane are former employees of Bristol-Myers Squibb. Currently, Roger Lane is an employee of Ionis Pharmaceuticals, Inc., and has stocks. Harald Murck is the owner of Murck-Neuroscience LLC and has developed a patent related to the treatment of refractory major depression. Robert Risinger is a current employee of BioXcel Therapeutics Inc. Lieuwe Appel, Anders Wall, and Gunnar Antoni, former GE Healthcare Uppsala Imanet employees, declare no financial relationships with commercial interests.